Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis
Terminated · Phase 3 · NCT05962788
Conditions: Adolescent Lupus Nephritis, Pediatric Lupus Nephritis
At a glance
- Research payments reported, 2025
- $39,150
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 4
About the trial
- Sponsor
- Aurinia Pharmaceuticals Inc.
- Tested
- voclosporin (drug)
- Dates
- Started 2024-03-28; completion 2025-07-04
- Results posted
- Not yet
The purpose of this study is to assess the long-term safety and tolerability of voclosporin for up to an additional 12 months following completion of treatment in the AUR-VCS-2020-03 study (VOCAL) in adolescent and pediatric subjects with lupus nephritis.
From ClinicalTrials.gov, last updated 2026-02-10. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Aurinia Pharma U.S., Inc. reported $39,150 in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.